Inozyme Pharma, Inc. is a high-risk pharmaceutical company based in the USA that is focused on developing innovative therapeutics for rare diseases affecting the vasculature, soft tissue, and skeleton. The company is dedicated to addressing the underlying causes of these debilitating conditions, particularly ENPP1 and ABCC6 Deficiencies. Their product candidate, INZ-701, is a genetically engineered fusion protein designed to correct defects in the ESG pathway related to these genetic disorders. With an ESG score of 33.1, Inozyme Pharma, Inc. is a leading player in the field of rare disease biopharmaceuticals.